Lineage Cell Therapeutics Inc

ASE:LCTX  
2.25
+0.08 (+3.69%)
Products

Lineage Cell Therapeutics Presents Additional Interim Data On OpRegen

Published: 03/23/2021 12:28 GMT
Lineage Cell Therapeutics Inc (LCTX) - Lineage Cell - Announced New Positive Interim Results From Ongoing, 24-patient Phase 1/2a Clinical Study of Lead Product Candidate, Opregen.
Lineage Cell Therapeutics Inc - Seventy-five Percent of All Cohort 4 Patients Have Experienced Bcva Increases.
Lineage Cell - No Acute Or Delayed Inflammation Or Rejection of Opregen Observed, Even in Patients Treated With Reduced Immunosuppressive Regimen.
Lineage Cell Therapeutics Inc - Overall, Opregen Has Been Well Tolerated With No Unexpected Adverse Events Or Serious Adverse Events.